Cytek Biosciences, Inc.
CTKB · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $432 | $515 | $839 |
| - Cash | $93 | $75 | $95 | $99 |
| + Debt | $22 | $14 | $16 | $17 |
| Enterprise Value | – | $370 | $435 | $757 |
| Revenue | $52 | $46 | $41 | $57 |
| % Growth | 14.7% | 10% | -27.9% | – |
| Gross Profit | $28 | $24 | $20 | $34 |
| % Margin | 52.7% | 52.3% | 48.6% | 58.5% |
| EBITDA | -$4 | -$3 | -$8 | -$2 |
| % Margin | -8.1% | -7.4% | -19.5% | -4.3% |
| Net Income | -$5 | -$6 | -$11 | $10 |
| % Margin | -10.5% | -12.2% | -27.5% | 16.8% |
| EPS Diluted | -0.04 | -0.044 | -0.09 | 0.073 |
| % Growth | 9.1% | 51.1% | -224% | – |
| Operating Cash Flow | -$4 | $0 | -$0 | $2 |
| Capital Expenditures | -$1 | -$2 | -$1 | -$1 |
| Free Cash Flow | -$5 | -$1 | -$1 | $1 |